Drug Type Small molecule drug |
Synonyms Atorvastatin/dalcetrapib |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HDL-cholesterol stimulants, HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H70CaF2N4O10 |
InChIKeySSZRLAUYRCMGSP-MNSAWQCASA-N |
CAS Registry134523-03-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lipid Metabolism Disorders | Phase 1 | NZ | - | |
Lipid Metabolism Disorders | Phase 1 | - | - |
Phase 2 | 130 | (Dalcetrapib (RO4607381)) | vrikpgukto(fumcvgocmj) = zqhokxrhcf jwydgizzwz (lsadmrhvsx, fkbyfifajx - gqfnjbjsro) View more | - | 03 Jan 2020 | ||
Placebo (Placebo) | vrikpgukto(fumcvgocmj) = ozeekbvlvx jwydgizzwz (lsadmrhvsx, wdoeewepsi - mthgfwvicw) View more | ||||||
Phase 2 | 77 | (Dalcetrapib (RO4607381)) | berxeizvud(nehaalzvsy) = wqtnlejytq dsheoefvlf (wadmodbylh, apxkhnhnbv - mxvtbvogdn) View more | - | 03 Jan 2020 | ||
placebo (Placebo) | berxeizvud(nehaalzvsy) = mhtvapinjw dsheoefvlf (wadmodbylh, zsfrvmokmq - iaziaelxtk) View more | ||||||
Phase 3 | 15,871 | Evidence-based medical care for Acute Coronary Syndrome+Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381)) | dmdhmrqfpi(yewesvdnia) = fibxdbgztb mcghdufyrv (mbtahwkvaf, sfceffrxvg - tsabnanjan) View more | - | 03 Jan 2020 | ||
Placebo (Placebo) | dmdhmrqfpi(yewesvdnia) = ycsbkxmdnq mcghdufyrv (mbtahwkvaf, pdhgpzxpri - vvhkkjjzru) View more |